Dr. Bosse on Challenges With Immunotherapy in Pediatric Cancers

Kristopher Bosse, MD
Published: Wednesday, Aug 08, 2018



Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses challenges with immunotherapy in pediatric cancers.

Bosse says that choosing the correct immunotherapy for pediatric patients with solid tumors is a challenge. There are some immunotherapies in the pipeline being developed to target certain molecules in neuroblastoma, but finding targets has proven difficult.

As a result of the success of chimeric antigen receptor T-cell therapy, CD19 has become the gold standard, Bosse says. There are very few other molecules like that on pediatric cancers, posing a challenge in developing new cellular therapies and immunotherapeutics.

Cancers are very apt to developing resistance mechanisms to potent therapies by losing antigens or switching lineage, which can allow them to hide, Bosse explains. Combination therapies, or dual-targeting immunotherapeutics may be an approach to overcome this, he suggests.
SELECTED
LANGUAGE


Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses challenges with immunotherapy in pediatric cancers.

Bosse says that choosing the correct immunotherapy for pediatric patients with solid tumors is a challenge. There are some immunotherapies in the pipeline being developed to target certain molecules in neuroblastoma, but finding targets has proven difficult.

As a result of the success of chimeric antigen receptor T-cell therapy, CD19 has become the gold standard, Bosse says. There are very few other molecules like that on pediatric cancers, posing a challenge in developing new cellular therapies and immunotherapeutics.

Cancers are very apt to developing resistance mechanisms to potent therapies by losing antigens or switching lineage, which can allow them to hide, Bosse explains. Combination therapies, or dual-targeting immunotherapeutics may be an approach to overcome this, he suggests.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x